Martín Zarbá

[Toni Choueiri, MD @DrChoueiri]

Work from @IMDConline here led by @ZarbaMartin1 showing that CR in 1L metastatic RCC have an excellent prognosis, though does not always guarantee cure

https://t.co/clyIIf2LnL

@DrDanielHeng @DrVaishampayan @Prof_IanD @jpsade2 @ConnorWells_95

[Daniel C. @pharma_gen_dan]

@DrChoueiri @IMDConline @ZarbaMartin1 @DrDanielHeng @DrVaishampayan @Prof_IanD @jpsade2 @ConnorWells_95 @UCalgaryMed @DanaFarber_GU @DanaFarberNews @DanaFarber @RazaneHChehade @KarlSemaan @DrRanaMcKay @CPRT65 @g_develasco @crisuarez08 6.2% versus 1.5%. The durability heterogeneity between IO and VEGF regimens challenges our progression protocols. Essential Canadian contribution to this IMDC analysis.

[Complete Response 🇧🇷 - Oncology Updates & Cases @resp_completa]

@DrChoueiri @IMDConline @ZarbaMartin1 @DrDanielHeng @DrVaishampayan @Prof_IanD @jpsade2 @ConnorWells_95 @UCalgaryMed @DanaFarber_GU @DanaFarberNews @DanaFarber @RazaneHChehade @KarlSemaan @DrRanaMcKay @CPRT65 @g_develasco @crisuarez08 Excellent work - congratulations on this important contribution. Patients with CR show a favorable prognosis despite not being cured. Future studies may help define the role of local therapy after CR and identify molecular profiles to guide selection for IO rechallenge.

[Heber Reyes, MD @heberolimus]

Congratulations, @ZarbaMartin1!

[Martín Angel @Martin_AngelMD]

Happy to collaborate with #IMDC team
Thanks @OfficialDrMaj @DrDanielHeng @ZarbaMartin1 #ASCO25

[Heber Reyes, MD @heberolimus]

Also had the chance to greet fellows from @IMDConline, kudos on your posters! @ZarbaMartin1 + @OfficialDrMaj Hope to see you all soon. 🍁 @DrDanielHeng @calgaryhealth

[Daniel Heng @DrDanielHeng]

. @IMDConline posters today. Proud of the fellows @MartinZarba1 #Davidmaj @AHS_media @UCalgaryMed @Charb_Cancer who commit so much time and energy to… research never stops. #kidneycancer @OncoAlert

[Daniel Heng @DrDanielHeng]

I love our team! Thanks for representing at #GU25 in San Francisco. I love this conference. So much learning and connecting. @IMDConline #AmazingFellows @UCalgaryMed @albertacancer @asco #GU25 @Nimira_A @Yipilimumab @DrTakemura @DrJeffreyGraham @AudreylieL

[Daniel Heng @DrDanielHeng]

Congratulations to all the #NOYCIA award winners last night including @MartinZarba @mattwrkntn from @UCalgaryMed @albertacancer Cancer research always matters and patients urgently need it. Thanks for moving the needle forward. @IMDConline #ASCO24 #oncoalert #YYC 🇨🇦 🇨🇦 🇨🇦

[UroToday.com @urotoday]

Systemic Treatments in favorable and very favorable risk metastatic #RenalCellCarcinoma: Real-world evidence from the International @mRCC Database Consortium. Presented by @ZarbaMartin1. #ASCO24 written coverage by @RKSayyid > https://t.co/1FVjj3jT6y @ASCO

[Yüksel Ürün @DrYukselUrun]

More data form @IMDConline
🟠Better patient stratification more precise treatment decision!
🟠In the very favorable risk subgroup, Ipilimumab + Nivolumab showed decreased 2-year overall survival compared to VEGF inhibitors.
@HamidMD10 @jacobadashek @twooncdocs @DarcyBurbage @fumikochino @JaniceTNBCmets @devikadasMD @ADesaiMD @elbairikhalid19 @jillfeldman4 @OncBrothers @TheFellowOnCall @herbloong @anavmanana @Charbel_matar1 @TheDrWood @DrMMurphy @thenasheffect @ARosen380 @ramsedhom @AshleysumrallMD @KekoaMDPhD @drteplinsky @ShannonWestin @oncoalert #ASCO24 @ASCO @Larvol

[Michael Serzan, MD @MikeSerzanMD]

⭐️ RAPID ORALS RENAL ⭐️

“Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).”

Dr Martin Zarba @DrDanielHeng

IMDC FAV (n = 611)

✅ Nivo/Ipi: ORR (35%), 2yr OS 86.4%
✅ IO/TKI: ORR (51.4%), 2yr OS 84.1%
✅ TKI: ORR (37.9%), 2yr OS 81.1%

IMDC VERY FAV (n= 165)
(Dx to systemic therapy ≥3yr,
KPS > 90, and no brain, liver, or bone metastasis)

✅ Nivo/Ipi: ORR (23.5%), 2yr OS 71.3%
✅ IO/TKI: ORR (58.1%), 2yr OS 87.2%
✅ TKI: ORR (55%), 2yr OS 92.1%

[Tom Powles @tompowles1]

The debate for treatment of IMDC good risk continues #ASCO24 . The data presented supports the ESMO weak recommendations for ipi/nivo in the good risk population, but it doesn’t look so good in the rare very good risk group - while this could be noise it could also be biology.

[Martín Angel @Martin_AngelMD]

Great presentation by @ZarbaMartin1 at #ASCO24
A subgroup analysis of #IMDC of favorable and very favorable risk patients.
Still a #VEGF inhibitors are the pillar of treatment for this subgroup.

[Daniel Heng @DrDanielHeng]

Come see our #IMDC fellow @Martinzarba Saturday 8am Room S100bc present on the Favorable risk and VERY favorable risk metastatic #kidneycancer population for potential guidance on therapy selection. #IMDConline @DrChoueiri @montypal @tompowles1 @ravikanesvaran @OncoAlert #ASCO24

[Toni Choueiri, MD @DrChoueiri]

Great presentation by Martin Zarba discussing therapeutic options in pts with favorable and very favorable risk #mRCC from the #IMDC database!

@DrDanielHeng @TalalZarif1 @eddy_saad @KarlSemaan
@ASCO @Oncoalert #ASCO24

[Tom Powles @tompowles1]

The IMDC story continues with a new very favourable group (good risk with no visceral mets and 3yrs since surgery).All the pts did well but Ipi/nivo was least impressive. Modest numbers & patient selection confounding, but there are VEGF mono sensitive slow growing tumors #ASCO24

[Martín Zarbá @ZarbaMartin1]

#NuevaFotoDePerfil

[Martín Zarbá @ZarbaMartin1]

@DrChoueiri @DrDanielHeng @TalalZarif1 @eddy_saad @KarlSemaan @ASCO @OncoAlert @DrRanaMcKay @yekeduz_emre @DrYukselUrun @ZiadBakouny @Chrislabaki1 @ReneeSaliby @Clara__Steiner @RazaneHChehade Many thanks @DrChoueiri , @DrDanielHeng and all the IMDC for the help and support for this project!!